Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China
In the era of precision medicine, with the deepening of the research on malignant tumor driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small-cell lung cancer (NSCLC), the development of targeted drugs targeting driver genes, such as epidermal growth factor re...
Main Authors: | Tao Li MD, Wen-Yu Yang BS, Ting-Ting Liu MD, Yao Li MD, Lu Liu MD, Xuan Zheng MD, Lei Zhao MD, Fan Zhang MD, Yi Hu MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-01-01
|
Series: | Technology in Cancer Research & Treatment |
Online Access: | https://doi.org/10.1177/15330338221148802 |
Similar Items
-
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC
by: Justin F. Gainor, MD, et al.
Published: (2020-09-01) -
RET Fusion Testing in Patients With NSCLC: The RETING Study
by: Esther Conde, MD, PhD, et al.
Published: (2024-04-01) -
RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
by: Badi El Osta, MD, et al.
Published: (2020-09-01) -
Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
by: Sai-Hong Ignatius Ou, MD, PhD, et al.
Published: (2020-06-01) -
LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
by: Marliese Alexander, B.Pharm(Hons), MPH, PhD, et al.
Published: (2023-04-01)